UCB
UCB.BR Large CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
UCB en bref
UCB (UCB.BR) is currently trading at 222,90 € with a market capitalization of 36,8 Md €. The trailing P/E ratio stands at 19.69x, with a forward P/E of 16.27x. The 52-week range spans from 181,15 € to 289,50 €; the current price is 23% below the yearly high. Year-over-year revenue growth stands at +22.5%. The net profit margin stands at 25.74%.
💰 Dividende
UCB pays an annual dividend of 1,45 € per share, representing a yield of 0.65%. The payout ratio stands at 12.81%.
📊 Avis des analystes
19 analystes évaluent UCB (UCB.BR) au consensus : Acheter. L'objectif de cours moyen est de 287,21 €, soit un potentiel de +28.85% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 195,00 € à 340,00 €.
UCB : la thèse d'investissement en détail
UCB (UCB.BR) operates in the Healthcare — specifically Biotechnology — and is headquartered in Belgium. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 22.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 134.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 76.22%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
À surveiller
- The forward P/E of 16.27x is meaningfully below the trailing 19.69x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 28.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 22.5% sur un an
- Rentable avec une marge nette de 25.74%
- Rentabilité élevée des capitaux propres (20.57% ROE)
- Marge brute élevée de 76.22% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 30.79)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy UCB?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news